{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:33:18Z","timestamp":1761129198106},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jviromet.2014.11.027","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T20:59:12Z","timestamp":1419022752000},"page":"29-32","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy"],"prefix":"10.1016","volume":"214","author":[{"given":"Christoph","family":"Sarrazin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Cloherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Chevaliez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Michel","family":"Pawlotsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2014.11.027_bib0005","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1128\/JCM.01320-07","article-title":"Improved Cobas TaqMan hepatitis C virus test (version 2.0) for use with the high pure system: enhanced genotype inclusivity and performance characteristics in a multisite study","volume":"45","author":"Colucci","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(13)61415-4","article-title":"Faldaprevir plus pegylated Interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from Startverso1, a randomised, double-blind, placebo-controlle phase III trial","volume":"58","author":"Ferenci","year":"2013","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.jviromet.2014.11.027_bib0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3851\/IMP2760","article-title":"Hepatitis C virus RNA quantification with different assays: implications for protease inhibitor-based response guided therapy","volume":"19","author":"Fevery","year":"2014","journal-title":"Antivir Ther."},{"issue":"3","key":"10.1016\/j.jviromet.2014.11.027_bib0030","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2013.11.007","article-title":"Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor Ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2014.11.027_bib0035","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/hep.24791","article-title":"Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment","volume":"55","author":"Harrington","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2014.11.027_bib0040","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C","volume":"49","author":"Kau","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2013.02.009","article-title":"A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450\/r, ABT-072) and ribavirin in IL28B C\/C patients with chronic hepatitis C genotype 1","volume":"59","author":"Lawitz","year":"2013","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.jviromet.2014.11.027_bib0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/apt.12544","article-title":"Detection of low HCV viremia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir","volume":"39","author":"Maasoumy","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(13)61412-9","article-title":"Simeprevir (TMC435) with PegInterferon\/Ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial","volume":"58","author":"Manns","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2013.05.002","article-title":"Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple-therapy: a comparison of two real-time PCR assays","volume":"99","author":"Ogawa","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0065","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics","volume":"310","author":"Osinusi","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jviromet.2014.11.027_bib0070","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1002\/hep.1840360709","article-title":"Use and interpretation of virological tests for hepatitis C","volume":"36","author":"Pawlotsky","year":"2002","journal-title":"Hepatology"},{"issue":"Suppl. 5","key":"10.1016\/j.jviromet.2014.11.027_bib0075","doi-asserted-by":"crossref","first-page":"S323","DOI":"10.1016\/j.dld.2013.07.007","article-title":"The importance of HCV RNA measurement for tailoring treatment duration","volume":"45","author":"Peiffer","year":"2013","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0085","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0090","series-title":"HepDart Meeting","article-title":"Appropriate use of Abbott RealTime HCV RNA assay in the management of HCV patients treated with telaprevir-based regimen: a retrospective analysis of the optimize study","author":"Sarrazin","year":"2013"},{"key":"10.1016\/j.jviromet.2014.11.027_bib0095","series-title":"Asia Pacific Association for the Study of the Liver Meeting","article-title":"Predicting response to all-oral directly acting antiviral therapy for hepatitis C using results of Roche and Abbott HCV viral load assays","author":"Sidharthan","year":"2014"},{"key":"10.1016\/j.jviromet.2014.11.027_bib0100","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0105","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/0091270003258669","article-title":"The global burden of hepatitis C","volume":"44","author":"The Global Burden of Hepatitis C Working Group","year":"2004","journal-title":"J Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.jviromet.2014.11.027_bib0115","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jhep.2014.01.002","article-title":"Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection","volume":"60","author":"Vermehren","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcv.2011.07.007","article-title":"Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C","volume":"52","author":"Vermehren","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jviromet.2014.11.027_bib0125","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/hep.22165","article-title":"Changing trends in hepatitis C-related mortality in the United States, 1995\u20132004","volume":"47","author":"Wise","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl.","key":"10.1016\/j.jviromet.2014.11.027_bib0130","first-page":"750A","article-title":"On-treatment HCV RNA as a predictor of virologic response in sofosbuvir-containing regimens for genotype 2\/3 HCV infection: analysis of the Fission, Positron and Fusion studies","volume":"58","author":"Wyles","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2014.11.027_bib0135","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and deleobuvir for HCV genotype 1 infection","volume":"369","author":"Zeuzem","year":"2013","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093414004741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093414004741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T17:23:54Z","timestamp":1537982634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093414004741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":25,"alternative-id":["S0166093414004741"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2014.11.027","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2014.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}